StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories diagnostics Segment — COVID-19 Testing YoY Impact on Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q4 2025
-3.4%
Period ended Dec 31, 2025
Change on a year earlier
+1.7 pts
-5.1% in Q4 2024
History
10 quarters
Since Q2 2023
Sources
10
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiagnostics Segment — COVID-19 Testing YoY Impact on Sales Growth (%) (%)Year on yearSource
Q4 2025Dec 31, 2025-3.4%+1.7 ptsSEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 2025-8.2%-6.3 ptsSEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 2025-2.2%+5.2 ptsSEC Filing (0001628280-25-035135) ↗
Q4 2024Dec 31, 2024-5.1%+19.4 ptsSEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 2024-1.9%+40.1 ptsSEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 2024-7.4%+44.4 ptsSEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 2024-20.9%–SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 2023-24.5%–SEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 2023-42.0%–SEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 2023-51.8%–SEC Filing (0001628280-23-025156) ↗

Cite this data

StockData. (2026). Abbott Laboratories Diagnostics Segment — COVID-19 Testing YoY Impact on Sales Growth (%) (%), quarterly Q2 2023–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-covid-impact-yoy

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.